FTSE MIB
33.794,69 -476,43 (-1,39%) Dow Jones
37.795,64 -665,28 (-1,73%) Nasdaq
15.428,99 -283,76 (-1,81%) Nikkei 225
37.628,48 -831,60 (-2,16%) Bitcoin EUR
59.306,35 -2.521,93 (-4,08%) CMC Crypto 200
1.370,16 -12,42 (-0,90%)
Outlook Therapeutics Inc (41ON.BE)
| Chiusura precedente | 0,3000 |
| Aperto | 0,3180 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,2860 - 6,0000 |
| Intervallo di 52 settimane | 0,2860 - 36,8000 |
| Volume | |
| Media Volume | 17 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 14 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireOutlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) dated August 29, 2023 regarding the Biologics License Application (BLA) for ONS-5010, an investigat
- GlobeNewswire
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ETISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
- GlobeNewswire
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Live video webcast presentation on Wednesday, September 13th at 9:30 AM ETISELIN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY
